Navigation Links
Virus might fight brain tumors better if armed with bacterial enzyme, study shows
Date:1/13/2011

COLUMBUS, Ohio New research shows that oncolytic viruses, which are engineered to destroy cancer cells, might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor.

The enzyme, called chondroitinase, helps the cancer-killing virus clear its way through the thickets of protein molecules that fill space between cells and impede the virus's movement through the tumor, say researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute who conducted the study.

When tested in animals transplanted with a human glioblastoma, the most common and deadly form of brain cancer, the enzyme-armed virus improved survival by 52 percent compared with controls and in some cases eliminated the tumor entirely.

The findings were published online in the journal Clinical Cancer Research.

"Our results show for the first time that an oncolytic virus with this enzyme can spread more effectively through the tumor and underscores the potential of using chondroitinases to enhance the capacity of oncolytic viruses to destroy cancer cells," says study leader Balveen Kaur, associate professor of neurological surgery.

The enzyme is derived from the intestinal bacterium called Proteus vulgaris. The enzyme removes sugar chains that branch from molecules called proteoglycans, which fill the narrow spaces between cells. By cutting away these branches, the enzyme clears a path that helps the virus spread through the tumor.

During this study, Kaur and her collaborators injected human glioblastoma cells under the skin of eight animals, and then, after tumors developed, treated the tumors with the enzyme-armed virus. These mice survived an average of 28 days, with two remaining tumor-free after 80 days. Control animals, treated with a virus that lacked the enzyme, survived 16 days.

In another experiment, mice with human gliobastomas transplanted into the brain survived 32 days versus 21 days for control animals, an improvement of 52 percent. Again, two animals lived more than 80 days and showed no trace of the tumor afterward.

Additional studies showed that the enzyme-laden virus had penetrated tumors in the animals' brain significantly better than the enzyme-free control virus.

"Overall, our results indicate that an oncolytic virus armed with this enzyme can have a significantly greater anticancer effect compared with a similar virus without the enzyme," Kaur says.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Scientists decode secrets of a very common virus that can cause cancer
2. Flu Viruses Gaining Resistance, Study Confirms
3. Influenza virus strains show increasing drug resistance and ability to spread
4. BUSM researchers show an oncolytic virus switches off cancer cell survival signal
5. Potential new treatment for deadly nipah and hendra viruses identified by Weill Cornell researchers
6. Scientists investigate evolution of new polio virus
7. Haptoglobin as an early serum biomarker of virus-induced type 1 diabetes in rats
8. New Virus Jumps From Monkey to Scientist, Causing Serious Illness
9. A redeeming role for a common virus
10. Childhood Obesity Might Be Linked to Strain of Cold Virus
11. Higher incidence of seizures seen in children with H1N1 virus compared to seasonal flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Tribble Insurance Agency, a family owned and operated firm offering ... charity event to honor Chad Phillip Dermyer, a local police trooper who was shot ... and his fellow officers were conducting routine stops of suspects when one of them, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive year, ... Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, ... been chosen by their peers for the 2017 list based on their exceptional ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales ... market. , Over the past 20 years SFI has been recognized as the world’s ... six new clients into the US market. The new clients include: Panacea Pro, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known ... Few people know that popular cosmetic fillers can enhance earlobes and ... medical director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
(Date:1/19/2017)... 2017  Magnetic Insight Inc., leader in magnetic ... agreement with inviCRO LLC to develop intuitive image ... based on inviCRO,s VivoQuant™ visualization and post processing ... complete MPI solution package with the Momentum MPI ... imaging in vivo. MPI is a ...
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
Breaking Medicine Technology: